Halozyme Therapeutics, Inc. (LON:0J2O)

Market Cap	5.58B
Revenue (ttm)	811.01M
Net Income (ttm)	354.73M
Shares Out	n/a
EPS (ttm)	2.74
PE Ratio	15.73
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73
Average Volume	759
Open	61.00
Previous Close	61.41
Day's Range	60.05 - 61.00
52-Week Range	30.09 - 58.75
Beta	n/a
RSI	52.21
Earnings Date	May 8, 2025

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 350
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J2O

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.

Financial numbers in USD